Apimeds Pharmaceuticals US, Inc (APUS) 10-Year Financial Performance & Capital Metrics

APUS • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsPain Management

AboutApimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.Show more

Revenue $0
EBITDA -$1M -72.0%
Net Income -$1M -78.7%
EPS (Diluted) -0.11 -79.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -10.83 +44.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-213.46%

EPS CAGR

10Y-

5Y-

3Y-

TTM-254.2%

ROCE

10Y Avg-440.69%

5Y Avg-440.69%

3Y Avg-250.18%

Latest-

Peer Comparison

Pain Management

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
COLLCollegium Pharmaceutical, Inc.	1.48B	46.90	25.22	11.41%	7.72%	21.27%	13.71%	3.75
PRFXPainReform Ltd.	3.21M	0.82	-0.03			-48.4%		0.02
PCRXPacira BioSciences, Inc.	848.72M	20.65	-9.60	3.85%	2.99%	2.95%	21.06%	0.82
APUSApimeds Pharmaceuticals US, Inc	21.76M	1.73	-15.73			-63.2%
ASRTAssertio Holdings, Inc.	71.42M	11.13	-48.39	-17.83%	-21.06%	-27.34%	36.98%	0.33

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	0	0
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	0	0
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-
Operating Expenses+	1.02M	639.53K	747.44K	1.28M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	529.55K	271.53K	648.89K	1.28M
SG&A % of Revenue	-	-	-	-
Research & Development	489.94K	368K	98.54K	0
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	0	0
Operating Income+	-1.02M	-639.53K	-747.44K	-1.28M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	0.37%	-0.17%	-0.71%
EBITDA+	-1.02M	-639.53K	-739.63K	-1.27M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	0.37%	-0.16%	-0.72%
D&A (Non-Cash Add-back)	0	0	0	0
EBIT	-1.02M	-639.53K	-739.63K	-1.27M
Net Interest Income+	-6.74K	-29.14K	-30.26K	-114.89K
Interest Income	0	0	7.81K	2.82K
Interest Expense	6.74K	29.14K	38.07K	117.72K
Other Income/Expense	-6.74K	-29.14K	-30.26K	-114.89K
Pretax Income+	-1.03M	-668.67K	-777.69K	-1.39M
Pretax Margin %	-	-	-	-
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-1.03M	-668.67K	-777.69K	-1.39M
Net Margin %	-	-	-	-
Net Income Growth %	-	0.35%	-0.16%	-0.79%
Net Income (Continuing)	-1.03M	-668.67K	-777.69K	-1.39M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.08	-0.05	-0.06	-0.11
EPS Growth %	-	0.35%	-0.16%	-0.79%
EPS (Basic)	-0.09	-0.06	-0.07	-0.12
Diluted Shares Outstanding	12.69M	12.69M	12.69M	12.69M
Basic Shares Outstanding	11.53M	11.53M	11.53M	11.53M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	172.17K	6.17K	422.08K	13.06K
Cash & Short-Term Investments	171.44K	6.17K	410.48K	3.46K
Cash Only	171.44K	6.17K	410.48K	3.46K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	0	0	11.6K	0
Total Non-Current Assets+	0	0	0	0
Property, Plant & Equipment	0	0	0	0
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	172.17K	6.17K	422.08K	13.06K
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.96%	67.4%	-0.97%
Total Current Liabilities+	10.65K	319.78K	123.31K	1.02M
Accounts Payable	10.65K	36.88K	0	0
Days Payables Outstanding	-	-	-	-
Short-Term Debt	0	260K	0	250K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	180.55K
Current Ratio	16.16x	0.02x	3.42x	0.01x
Quick Ratio	16.16x	0.02x	3.42x	0.01x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	400K	400K	266.89K	346.84K
Long-Term Debt	400K	400K	266.89K	346.84K
Capital Lease Obligations	0	0	0	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	410.65K	719.78K	390.2K	1.37M
Total Debt+	400K	660K	266.89K	596.84K
Net Debt	228.56K	653.83K	-143.59K	593.39K
Debt / Equity	-	-	8.37x	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-151.26x	-21.95x	-19.63x	-10.83x
Total Equity+	-238.48K	-713.61K	31.87K	-1.36M
Equity Growth %	-	-1.99%	1.04%	-43.61%
Book Value per Share	-0.02	-0.06	0.00	-0.11
Total Shareholders' Equity	-238.48K	-713.61K	31.87K	-1.36M
Common Stock	100K	100K	205.5K	79.04K
Retained Earnings	-1.56M	-2.22M	-3M	-4.39M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-823.11K	-448.17K	-627.79K	-733.53K
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	0.46%	-0.4%	-0.17%
Net Income	-1.03M	-668.67K	-777.69K	-1.39M
Depreciation & Amortization	0	0	0	0
Stock-Based Compensation	193.54K	193.54K	69.99K	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	6.74K	29.14K	38.07K	117.72K
Working Capital Changes	2.84K	-2.18K	41.84K	538.75K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	0	0
Cash from Investing+	0	0	0	0
Capital Expenditures	0	0	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	400K	282.9K	1.03M	326.5K
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	22.9K	-22.9K	76.5K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-823.11K	-448.17K	-627.79K	-733.53K
FCF Margin %	-	-	-	-
FCF Growth %	-	0.46%	-0.4%	-0.17%
FCF per Share	-0.06	-0.04	-0.05	-0.06
FCF Conversion (FCF/Net Income)	0.80x	0.67x	0.81x	0.53x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-2440.13%	-
Debt / Equity	-	-	8.37x	-
Interest Coverage	-151.26x	-21.95x	-19.63x	-10.83x
FCF Conversion	0.80x	0.67x	0.81x	0.53x

Frequently Asked Questions

Growth & Financials

Apimeds Pharmaceuticals US, Inc (APUS) grew revenue by 0.0% over the past year. Growth has been modest.

Apimeds Pharmaceuticals US, Inc (APUS) reported a net loss of $5.2M for fiscal year 2024.

Dividend & Returns

Apimeds Pharmaceuticals US, Inc (APUS) had negative free cash flow of $5.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener